Targeting emerging amino acid dependencies and transporters in cancer therapy

Area of Science:

• Oncology
• Metabolic pathways in cancer

Background:

• Amino acid metabolism represents a critical vulnerability in cancer.
• Established strategies like arginine depletion and glutaminase inhibition show targeting potential.
• Clinical trials face challenges with tumor metabolic adaptation and the need for predictive biomarkers.

Purpose of the Study:

• To review emerging amino acids (histidine, isoleucine, threonine, lysine, alanine) as novel metabolic targets in cancer.
• To discuss the translational opportunities and challenges for these targets.
• To emphasize the role of amino acid transporters in nutrient uptake, biomarker development, and therapeutic strategies.

Main Methods:

• Review of current scientific literature on amino acid metabolism in cancer.
• Analysis of preclinical models and clinical trial data.
• Focus on the biology of amino acid transporters.

Main Results:

• Histidine and isoleucine show selective cytotoxicity to pancreatic cancer cells in preclinical models.
• Threonine supports glioblastoma growth via codon-biased protein synthesis.
• Lysine breakdown impacts interferon signaling, while alanine fuels therapy-resistant metabolism.

Conclusions:

• Histidine, isoleucine, threonine, lysine, and alanine are emerging as significant metabolic targets in oncology.
• Amino acid transporters are crucial for nutrient availability and serve as potential biomarkers.
• Further research into transporter biology, biomarker development, and combination therapies is essential for clinical translation.